Starling Oncology Inc. (STLN)
NASDAQ: STLNHealth CareMedical/Nursing ServicesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
STLN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $305.97M
- EPS (TTM)
- -$0.28
- Dividend yield
- None
- 52-week range
- 2.32 – 7.13
- Day range
- 2.97 – 3.27
- Volume / Avg
- 5.86M / 2.55M
- Beta
- —
- Shares outstanding
- 101.99M
52-week range
STLN stock today
On Nov 20, STLN ended the session at $3.00, shedding $0.18 (5.66%), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 5.86M shares, a sign of unusually heavy trading. Shares are 57.9% below their 52-week high of $7.13, set on Sep 18, 2026 and 29.3% above the 52-week low of $2.32, near the bottom of the past year's range.
STLN is down 15.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.2%. Starling Oncology has posted a net loss over the last twelve months (EPS of -$0.28), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Starling Oncology
Company profileStarling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services.
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- CEO
- Dr. Daniel Virnich FACHE, M.B.A., M.D.
- Headquarters
- Cerritos, CA
- Employees
- 641
- IPO year
- 2020
- Website
- starlingoncology.com
Financial highlights
Full financialsIn fiscal 2025, Starling Oncology generated $502.7 million in revenue, up 27.8% from fiscal 2024, its 5th consecutive year of revenue growth. Starling Oncology reported a net loss of $60.6 million, compared with a loss of $64.7 million a year earlier. Operating margin was -7.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $502.73M | $393.41M | $324.24M | $252.48M | $203.00M |
| Growth | +27.79% | +21.33% | +28.42% | +24.37% | +8.26% |
| Net income | $-60.61M | $-64.66M | $-83.07M | $152.00K | $-10.93M |
| EPS (diluted) | $-0.54 | $-0.71 | $-0.92 | $-0.21 | $-0.16 |
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$9.25+208.33%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.14 vs $-0.07
- Surprise
- -100.00%
STLN news
All STLN news- Notable Friday Option Activity: STLN, CAR, BXNasdaqSTLN, CAR, BX
- Friday Sector Laggards: Hospital & Medical Practitioners, Packaging & ContainersNasdaqAIRS, STLN, KRT, OI
- Starling Oncology expects $650M-$660M revenue and $4M-$6M adjusted EBITDA in 2026 while targeting 100% capitated revenue growth in 2027Seeking Alpha
- Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 GuidanceGlobeNewswire
- Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference CallGlobeNewswire
Starling Oncology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AUNAAuna SA Class A | 3.66 | -6.15% | $271.05M | vs STLN |
| PIIIP3 Health Partners Inc. Class A | 1.69 | -9.14% | $350.24M | vs STLN |
| SRTAStrata Critical Medical Inc. Class A | 4.56 | -5.59% | $407.30M | vs STLN |
| SBCSBC Medical Group Holdings Incorporated | 5.17 | -7.68% | $530.32M | vs STLN |
| LFMDLifeMD Inc. | 1.45 | -9.40% | $69.84M | vs STLN |
| NAKANakamoto Inc. | 3.44 | -15.89% | $63.11M | vs STLN |
| EUDAEUDA Health Holdings Limited Class A | 15.96 | -7.69% | $47.79M | vs STLN |
| AIRSAirSculpt Technologies Inc. | 0.5907 | -9.72% | $43.67M | vs STLN |
Indexes, lists and sector
Starling Oncology stock FAQ
What is Starling Oncology's stock price today?
STLN last traded at $3.00 as of Nov 20, 4:00 PM EST, down 5.66% on the day. Prices are delayed at least 15 minutes.
Who is Starling Oncology's CEO?
Dr. Daniel Virnich FACHE, M.B.A., M.D. is the chief executive officer of Starling Oncology Inc., which has about 641 employees.
What is the STLN 52-week high?
The 52-week high for STLN is $7.13 and the 52-week low is $2.32. The stock is currently 57.9% below its high.